MedTech News
.................... by Andrew Celentano
AI model flags insulin resistance as a risk factor for 12 cancers
For the first time, researchers, including those from the University of Tokyo, applied a machine learning-based prediction model of insulin resistance to half a million participants from the UK Biobank and demonstrated that insulin resistance is a risk factor for 12 types of cancer.
A 15-minute VR eye test could flag vision changes tied to brain health
In the recreation room at Eskaton Village in Carmichael, Bonnie Dale, one of the residents, is trying on a virtual reality (VR) headset.
A patch that sticks inside your mouth could spot inflammation early
The specialized sensing layer of the patch targets the tumor necrosis factor-alpha (TNF-⍺) protein, a key biomarker for inflammation.
Philips introduces flexible pediatric MRI coil
Philips (NYSE: PHG)+ announced that it launched the InkSpace Imaging Snuggle pediatric body array coil for its 3.0T MRI systems.
Novocure wins FDA approval to treat pancreatic cancer with electric fields
Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.
EYE PCR Receives CE Mark for fixOflex Endocapsular Device, Enabling European Market Introduction
HERAKLION, Greece, Feb. 13, 2026 /PRNewswire/ — EYE PCR announces that its fixOflex endocapsular device has received CE Mark certification under the European Union Medical Device Regulation (EU MDR 2017/745), enabling commercialization in Europe and other markets that recognize the CE Mark. This regulatory milestone validates the device’s safety and efficacy, positioning EYE PCR for controlled market introduction.
InVera Medical Achieves European CE Mark Approval for New Vein Infusion Device
GALWAY, Ireland, Feb. 13, 2026 /PRNewswire/ — InVera Medical, an Irish medical technology company, has received European regulatory approval for a new minimally invasive device designed to help physicians deliver treatment more effectively to diseased leg veins, including varicose veins.
World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors
TAICHUNG, Feb. 13, 2026 /PRNewswire/ — Cancer has long ranked among the leading causes of death in Taiwan, and solid tumors account for more than 90% of cancer cases worldwide—making them the most challenging frontier for CAR-T cell therapy. China Medical University Hospital (CMUH) announced today that, in collaboration with Ever Supreme Bio Technology, it has successfully developed the world’s first EXO 001 targeted exosome platform, a breakthrough technology that enables direct in vivo programming of T cells to generate multi-target nanobody-based CAR-T cells.